All posts

Follow Us

LinkedInInstagramX
Quarterly ResultsArchiveLast updated 22 November 20263 min read

Goldline (GLPL) Q2 FY27 Pharma Profit Soars 51% as Debt Repayment Cuts Costs

Goldline Pharmaceutical's Q2 FY27 net profit surged 50.7% year-on-year, driven by a sharp reduction in interest expenses following a major debt repayment funded by fresh equity.

By Abhinav Singhvi, Founder & CEO Hexawealth · Created 16 November 2026

Goldline Pharmaceutical's Q2 FY27 profit jumped 51% year-on-year to ₹2.05 crore, even as revenue grew modestly. The profit surge was fueled by a 58% drop in interest costs after the company used fresh equity to repay debt.

For a small pharmaceutical marketer, the cost of capital often dictates the bottom line. Goldline Pharmaceutical's September quarter delivered a clear win on that front, with profit soaring over 50% on a modest sales increase as a heavy debt burden lifted.

The numbers show a company in transition. Revenue for Q2 FY27 was ₹14.93 crore, up 7.5% from a year ago but down 13.7% sequentially. Net profit, however, leapt to ₹2.05 crore, a 50.7% year-on-year gain. The net profit margin expanded to 13.7%, a significant 390 basis point improvement from Q2 FY26.

Revenue & profit

Revenue (₹ Cr)

Profit (₹ Cr)

Revenue & profitQ2 FY26 13.89, Q4 FY26 17.31, Q2 FY27 14.93. Q2 FY26 1.36, Q4 FY26 2.76, Q2 FY27 2.0505101520Q2 FY26Q4 FY26Q2 FY27
  • Revenue (₹ Cr), Q2 FY26: 13.89
  • Revenue (₹ Cr), Q4 FY26: 17.31
  • Revenue (₹ Cr), Q2 FY27: 14.93
  • Profit (₹ Cr), Q2 FY26: 1.36
  • Profit (₹ Cr), Q4 FY26: 2.76
  • Profit (₹ Cr), Q2 FY27: 2.05

Revenue (₹ Cr)

Revenue (₹ Cr)Q2 FY26 13.89, Q4 FY26 17.31, Q2 FY27 14.9305101520Q2 FY26Q4 FY26Q2 FY27
  • Revenue (₹ Cr), Q2 FY26: 13.89
  • Revenue (₹ Cr), Q4 FY26: 17.31
  • Revenue (₹ Cr), Q2 FY27: 14.93

Profit (₹ Cr)

Profit (₹ Cr)Q2 FY26 1.36, Q4 FY26 2.76, Q2 FY27 2.0501234Q2 FY26Q4 FY26Q2 FY27
  • Profit (₹ Cr), Q2 FY26: 1.36
  • Profit (₹ Cr), Q4 FY26: 2.76
  • Profit (₹ Cr), Q2 FY27: 2.05

Net Profit Margin (%)

Net Profit Margin (%)Q2 FY26 9.8, Q4 FY26 15.9, Q2 FY27 13.70%5%10%15%20%Q2 '26Q4 '26Q2 '27
  • Net Profit Margin (%), Q2 FY26: 9.8
  • Net Profit Margin (%), Q4 FY26: 15.9
  • Net Profit Margin (%), Q2 FY27: 13.7
MetricCurrentQ2 FY27Same quarter LYQ2 FY26
Revenue (₹ Cr)
14.93YoY +7.5%
13.89
Profit (₹ Cr)
2.05YoY +51%
1.36
Net Profit Margin (%)
13.7YoY +40%
9.8

The interest expense that vanished

The primary driver of the profit jump was a dramatic fall in finance costs. According to a report from mcapital.in, the company repaid about ₹8.5 crore of debt using ₹11.61 crore raised from a fresh equity issue. This slashed interest expense by 58.2% year-on-year to just ₹0.28 crore, directly boosting the bottom line.

This financial engineering has fundamentally strengthened the balance sheet. The same report notes net worth nearly doubled to about ₹25.9 crore, while debt was drastically reduced. The trade-off, however, is earnings dilution from the increased share capital.

A sequential slowdown in sales

While the annual comparison is positive, the quarter-on-quarter picture is softer. Revenue fell from ₹17.31 crore in the March 2026 quarter. The research did not pinpoint a specific cause, but the broader domestic pharmaceutical market, as reported by Business Standard, showed robust 13.5% value growth in September, driven by both price and volume.

Live Chart

· GLPL

(BSE)

ISIN: INE1CLW01015

For Goldline, operating performance faced some pressure. Employee costs rose 34% year-on-year, according to mcapital.in, squeezing the operating margin. Furthermore, operating cash flow was a meagre ₹0.11 crore for the half-year, as a ₹2.59 crore working capital outflow, led by rising receivables, absorbed profits.

Key Points

  • Net profit surged 50.7% year-on-year to ₹2.05 crore, significantly outpacing a 7.5% revenue growth, due to a sharp reduction in interest costs.
  • The company executed a major deleveraging, repaying ₹8.5 crore of debt using fresh equity, which nearly doubled its net worth but diluted earnings per share.
  • Operating cash flow remained weak at ₹0.11 crore for the half-year, as increased trade receivables tied up capital despite improved profitability.

Hexa Perspective

The quarter tells a story of successful balance sheet repair over operational outperformance. The equity-funded debt repayment has created a cleaner, stronger platform for growth by removing a major cost drag. The challenge now is conversion.

Growth must come from the top line and better working capital management to turn accounting profits into cash. With a fortified equity base and minimal debt, the company has the stability to pursue this, but the recent sequential sales dip and stretched receivables show the path ahead is not automatic.

Share or follow HexaWealth

Also read

Want this applied to your portfolio?

Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.

Goldline Pharmaceutical (GLPL) Q2 FY27 results, revenue and profits.

Frequently asked questions

What were Goldline Pharmaceutical's Q2 FY27 results?
Goldline Pharmaceutical reported Q2 FY27 revenue of ₹14.93 crore, a 7.5% year-on-year increase. Net profit for the quarter was ₹2.05 crore, surging 50.7% from the same period last year, driven largely by a sharp reduction in interest expenses.
What drove Goldline Pharmaceutical's 50.7% profit surge in Q2 FY27?
The profit jump was primarily driven by a 58.2% year-on-year drop in interest expense. According to mcapital.in, the company repaid about ₹8.5 crore of debt using fresh equity proceeds, which drastically cut its finance costs and boosted the bottom line.
Why did Goldline Pharmaceutical's revenue decline sequentially in Q2 FY27?
Goldline's Q2 FY27 revenue of ₹14.93 crore was down 13.7% from the ₹17.31 crore reported in Q4 FY26. The research snippets did not specify a cause for this quarterly decline, which occurred despite a strong broader pharmaceutical market.
How did debt repayment affect Goldline Pharmaceutical's Q2 FY27 profitability?
Debt repayment was the key profit driver. Finance costs fell to ₹0.28 crore from ₹0.67 crore a year ago after the company used ₹11.61 crore from a share issue to repay ₹8.5 crore of borrowings, as reported by mcapital.in. This directly lifted net profit.
What was Goldline Pharmaceutical's net profit margin in Q2 FY27?
Goldline Pharmaceutical's net profit margin was 13.7% in Q2 FY27. This represents a strong 390 basis point improvement from the 9.8% margin in Q2 FY26, though it dipped 220 basis points from the 15.9% margin in the previous quarter.
What is the outlook for Goldline Pharmaceutical after Q2 FY27?
The company has strengthened its balance sheet significantly, with net worth nearly doubling. The focus now shifts to converting this stability into sales growth and improving cash flow, as operating margins faced pressure from higher employee costs and working capital absorbed cash.
What was Goldline Pharmaceutical's cash flow from operations in Q2 FY27?
Goldline Pharmaceutical's cash flow from operations was weak. For the half-year ended September 2026, it generated only ₹0.11 crore, as a ₹2.59 crore working capital outflow, mainly from rising receivables, offset its operating profit.
Did Goldline Pharmaceutical's Q2 FY27 results beat estimates?
Specific analyst estimates for the quarter were not detailed in the research. However, a report from mcapital.in characterized the half-year results as showing revenue up 7% and PAT up 45% YoY due to deleveraging, with a mixed impact from equity dilution and receivables growth.
How did Goldline Pharmaceutical's stock react to the Q2 FY27 results?
The stock's immediate reaction was not clear from the data. A MarketsMojo alert noted the last traded price was ₹29.27 on November 13, 2026, the day before the results were announced on November 14.
Goldline Pharmaceutical Q2 profit jump
Goldline Pharmaceutical's Q2 FY27 net profit jumped 50.7% year-on-year to ₹2.05 crore. This significant increase was largely due to a sharp 58% reduction in interest costs following a major debt repayment funded by a fresh equity issue.
Goldline Pharmaceutical Q2 FY27 results November 2026
Goldline Pharmaceutical announced its Q2 FY27 results on November 14, 2026. For the quarter ended September 2026, it reported revenue of ₹14.93 crore and a net profit of ₹2.05 crore, marking a 50.7% year-on-year profit increase.
Why did Goldline Pharmaceutical profits surge despite modest sales growth?
Goldline Pharmaceutical's profits surged 51% on modest 7.5% sales growth because of a drastic cut in interest costs. The company repaid ₹8.5 crore of debt using equity, which slashed its finance expense by 58% and flowed directly to the bottom line.